ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater China

ArriVent BioPharma reported second quarter 2026 financial results on August 12, 2026. Top-line data from the global pivotal FURVENT Phase 3 study for first-line EGFR exon 20 insertion mutant NSCLC is anticipated in 2H 2026.¹ The FURVENT trial has enrolled patients and is being run alongside a separate Phase 3 study, ALPACCA, in EGFR PACC mutant NSCLC.

On the pipeline side, ArriVent has initiated Phase 1b dose optimization for ARR-217, a CDH17 targeted ADC, in patients with gastrointestinal malignancies in partnership with Lepu Biopharma Co., Ltd.¹ Separately, ArriVent is advancing ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, into the clinic through a first-in-human study evaluating safety, dosing, and early signals of efficacy in patients with ovarian and endometrial cancers following Investigational New Drug clearance from the FDA in May 2026.¹ Dosing of the first patient with ARR-002 in a Phase 1 trial is expected in the third quarter of 2026.¹

On August 11, 2026, ArriVent entered a licensing deal with Shanghai Allist Pharmaceuticals. The company granted Allist an exclusive, sublicensable, royalty-bearing license to research, develop, manufacture, and commercialize ARR-002 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan, subject to ArriVent's retained right to manufacture ARR-002 in that territory.¹ ArriVent may be entitled to receive payments totaling as much as $80.6 million, comprised of a one-time upfront payment plus development, regulatory, and sales milestones, along with tiered royalties in the mid-single digit to low double-digit percentage range on net sales in the licensed territory.¹

Financially, as of June 30, 2026, the company had cash and investments of $373.1 million, expected to fund operations into 2028, while net cash used in operations was $81.5 million for the six months ended June 30, 2026, and net loss for the same period was $93.2 million.¹